<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336064">
  <stage>Registered</stage>
  <submitdate>7/02/2011</submitdate>
  <approvaldate>8/02/2011</approvaldate>
  <actrnumber>ACTRN12611000145909</actrnumber>
  <trial_identification>
    <studytitle>Nebulised pentoxifylline for the prevention of chronic lung disease in extremely preterm infants</studytitle>
    <scientifictitle>Does treating extremely preterm infants with inhaled Pentoxifylline vs Saline placebo lead to a reduction in chronic lung disease?</scientifictitle>
    <utrn>U1111-1117-3748</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bronchopulmonary dysplasia</healthcondition>
    <healthcondition>Premature birth</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Nebulised Pentoxifylline at 20 mg/kg (1ml/kg), 6 hourly for 10 days. If still ventilated or requiring&gt;= 30% oxygen 5 days after completing course, baby will receive a repeat 10 day course.</interventions>
    <comparator>Nebulised 0.9% sodium chloride at 1ml/kg in the same dosing regime as above.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Duration on supplemental oxygen (hours) at 40 week Post menstrual age.</outcome>
      <timepoint>At 40 weeks post menstrual age.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bronchopulmonary dysplasia or death</outcome>
      <timepoint>At 40 weeks post menstrual age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality to hospital discharge</outcome>
      <timepoint>At discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of hospital stay</outcome>
      <timepoint>At discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Preterm infants &lt; 28 w GA will be eligible for enrolment if they require mechanical ventilation greater than or equal to 30% supplemental oxygen at 72  168 h of life and if written informed parental consent is given.</inclusivecriteria>
    <inclusiveminage>23</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>27</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Congenital malformations of the thorax (e.g. congenital diaphragmatic hernia, congenital cystic adenomatoid malformation of the lung, esophageal atresia) 
Major cardiac malformations. (Infants with persistent ductus arteriosus or hemodynamically non-significant atrial or ventricular septal defect may be included in the trial).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Babies born between 23 weeks and 27 weeks plus 6 days will be enrolled following full informed parental consent. They will then be randomized to receive placebo or interventional drug. A randomisation list will be created by the coordinating trial pharmacist using a computer-based random number generator.Only the trial pharmacist will know contents of the trial drug. Everyone else will be blinded. The pharmacy will provde 1.5ml syringes of clear colourless undifferentiable liquid. These will then be nebulised in the standard way by the nursing staff as prescribed.</concealment>
    <sequence>Random number generator program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/03/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>King Edward Memorial Hospital, NCCU</primarysponsorname>
    <primarysponsoraddress>378 Bagot Road
Subiaco,
Perth
WA 6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>King Edward Memorial Hospital, NCCU</fundingname>
      <fundingaddress>378 Bagot Road
Subiaco,
Perth
WA 6008</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Chronic Lung Disease (Bronchopulmonary dyplasia) is a common and serious complication in extremely preterm infants below 28 weeks. In 2008 in Western Australia, over 120 infants were born at less than 28 weeks. 28% of the survivors developed Chronic lung disease.
With its immunomodulatory effects, Pentoxifylline is emerging as a promising treatment for conditions such as sepsis, NEC and Chronic Lung disease.
Whilst trials are encouraging for Pentoxifyllines effect on Chronic lung disease; well organized, properly blinded trials have not been published. This trial aims to address this and discover whether nebulized pentoxifylline might help prevent bronchopulmonary dysplasia in extremely preterm infants.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>King Edward Memorial Hospital Ethics Committee</ethicname>
      <ethicaddress>378 Bagot Road
Subiaco,
Perth
WA 6008</ethicaddress>
      <ethicapprovaldate>1/12/2009</ethicapprovaldate>
      <hrec>1763/EW</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>WNHS Ethics Committee</ethicname>
      <ethicaddress>373 Bagot Road, Subiaco. Perth, WA6008.</ethicaddress>
      <ethicapprovaldate>1/12/2009</ethicapprovaldate>
      <hrec>1763/EW</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sanjay Patole</name>
      <address>Neonatal Clinical Care Unit,
King Edward Memorial Hospital,
378 Bagot Road,
Subiaco,
Perth,
WA 6008</address>
      <phone>0061892408222</phone>
      <fax />
      <email>sanjay.patole@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Simon Pirie</name>
      <address>Neonatal Clinical Care Unit,
King Edward Memorial Hospital,
378 Bagot Road,
Subiaco,
Perth,
WA 6008</address>
      <phone>0061892408222</phone>
      <fax />
      <email>simon.pirie@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Simon Pirie</name>
      <address>Neonatal Clinical Care Unit,
King Edward Memorial Hospital,
378 Bagot Road,
Subiaco,
Perth,
WA 6008</address>
      <phone>0061892408222</phone>
      <fax />
      <email>simon.pirie@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>